Post-earnings recap
Reported
Thu, Jan 31, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alkermes' strong EPS performance indicates better-than-expected profitability, which likely contributed to the stock's 5.18% increase. Investors may be encouraged by the company's focus on its therapeutic areas and pipeline development. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.34 | N/A | +183.33% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a positive outlook regarding their current operations and future prospects, despite not providing specific guidance.
Management highlighted strong performance in their key therapeutic areas.
They expressed confidence in ongoing product development and pipeline progress.